Migraine Treatment Access: Why the Journey Is Long and How to Make It Faster

Migraine one of the leading causes of disability worldwide, affecting over 1 billion people according to the World Health Organization【WHO】. Yet, despite its impact, access to effective treatment is often long and frustrating.

Many patients describe a trial-and-error journey: starting with over-the-counter painkillers, moving through old medications with tough side effects, and only years later accessing newer migraine-specific treatments like anti-CGRPs or gepants.

Migraine Buddy data reflects this reality: among users who log their medications in the app, treatment patterns shift dramatically after diagnosis and as migraine becomes chronic. Meanwhile, surveys from our community show that 40% of users felt their doctor lacked migraine expertise and nearly 70% did not know if their insurance covered newer therapies【Healthcare System Support Survey】【Anti-CGRP Survey】.

The good news? With careful tracking, awareness of treatment pathways, and new options like telemedicine, patients can move faster toward the care they need.

1. Understanding Migraine Treatments

1.1 Migraine-Specific vs. Non-Specific Treatments

One of the most confusing parts of the journey is why doctors prescribe “non-migraine drugs” for migraine. It can feel discouraging, even scary, to take a blood pressure drug (propranolol) or an epilepsy drug (topiramate) for your head pain.

Here’s the truth: non-migraine-specific drugs can be highly effective in migraine prevention.

• Propranolol has been shown in trials to reduce monthly migraine frequency significantly【The Migraine Trust】.

• Antidepressants like amitriptyline help both with migraine and comorbid sleep/mood issues.

• Anticonvulsants like topiramate are proven preventives, though side effects can limit use.

Doctors prescribe these first because:

1. They are well-studied and evidence-based.

2. They are widely available and affordable.

3. Insurance often requires trying them before covering newer treatments.

Migraine-specific drugs (triptans, ditans, gepants, CGRPs, Botox, neuromodulation devices) target migraine biology directly. But non-specifics are not “second-class”, many patients benefit greatly from them.

1.2 Acute vs. Preventive

Acute treatments: taken during an attack to stop pain and symptoms.

• OTCs (ibuprofen, naproxen, acetaminophen, aspirin) → Cheap, widely available, but overuse can cause medication overuse headache (MOH)【AMF】.

• Triptans (sumatriptan, rizatriptan) → Migraine-specific, very effective, but carry cardiovascular risks【FDA】.

• Ditans (lasmiditan) → Migraine-specific, no vascular risks, but cause dizziness and drowsiness, so driving is restricted【FDA, 2019】.

• Gepants (ubrogepant, rimegepant) → Migraine-specific, safe in heart disease, generally well tolerated, but expensive.

• Antiemetics (metoclopramide, ondansetron) → Often added to treat nausea, either from migraine itself or as a side effect of other drugs.

• Opioids/barbiturates → Sometimes prescribed in ERs, but discouraged: poor efficacy, dependency risk【AMF】【MB Opioids Survey】.

Preventive treatments: taken regularly to reduce frequency and severity.

 First-generation (non-specific)

These older preventives weren’t designed for migraine but are proven to help many patients. They are usually prescribed first because they are affordable, widely available, and often effective.

• Beta-blockers (propranolol, metoprolol) → lower stress response, useful if the patient also has high blood pressure or anxiety. Risks: fatigue, dizziness, cold hands/feet.

• Anticonvulsants (topiramate, valproate) → stabilize nerve activity. Risks: brain fog, tingling, weight changes; valproate is restricted for women of childbearing age.

• Antidepressants (amitriptyline, venlafaxine) → adjust serotonin/norepinephrine, helpful if insomnia or depression are present. Risks: drowsiness, weight gain, dry mouth.

• Calcium channel blockers (verapamil, flunarizine) → relax blood vessels, sometimes used in cluster headache too. Risks: constipation, low blood pressure.

They may not feel “migraine-specific,” but they genuinely benefit many people and are the first step before trying newer preventives.

Second-generation (migraine-specific):

• CGRP monoclonal antibodies (Aimovig, Ajovy, Emgality, Vyepti) → Shown to cut monthly migraine days by half in many patients【The Migraine Trust】.

• Gepants (atogepant, rimegepant) → Daily preventive oral anti-CGRPs.

• Botox → Approved for chronic migraine (≥15 days/month), modest but proven effect【AMF】.

• Neuromodulation devices (Cefaly, gammaCore, sTMS) → Non-drug, safe, but limited access, usually not covered.

1.3 Typical Patient Pathway

Migraine Buddy app data shows a typical journey looks like this:

1. OTCs → often tried first, especially before diagnosis.

2. Triptans → once diagnosis is confirmed, many move here.

3. First-generation preventives → if migraine are frequent, patients are put on beta-blockers, anticonvulsants, or antidepressants.

4. Botox or anti-CGRPs → if first-gen preventives fail, patients move to newer migraine-specific preventives.

5. Gepants/Ditans for acute → for patients who cannot take triptans or who fail them.

6. Chronic migraine patients → log a much broader variety of treatments, including anti-nausea medications and muscle relaxants, reflecting complexity.

It’s not unusual to try 5–6 different treatments before finding one that works.

1.4 Migraine Buddy Data on Treatment Use

Among users who actively log medications in the Migraine Buddy app:

• Triptans are the most commonly tracked acute treatment.

• NSAIDs/OTCs are still widely relied upon, even after diagnosis, due to accessibility.

• Anti-nausea meds are frequently logged after triptans or preventives that trigger nausea.

• Chronic migraine patients record more preventives, more anti-nausea, and a wider spread of therapies overall compared to episodic patients.

📌 Note: These insights are based on in-app logs, not surveys. They reflect real-world use among patients who track consistently, but not all users log every medication.

2. Barriers to Treatment Access

2.1 Insurance Coverage

• United States: Most insurers require patients to fail 2–3 older preventives before covering Botox or CGRPs. Prior authorization and high co-pays are common barriers.

• United Kingdom: Under the NHS, CGRPs are only available if patients have ≥4 migraine days/month and have already failed ≥3 preventives. Access requires referral to a specialist.

• Australia: Through the national Pharmaceutical Benefits Scheme (PBS), CGRPs like Aimovig, Ajovy, Emgality and Vyepti, as well as Botox, are subsidized for patients meeting strict criteria (such as ≥15 migraine days/month or failure of multiple preventives). Recent policy changes even allow GPs to initiate prescriptions with specialist consultation, improving access in rural areas.

Important note: Each insurance provider and health plan has its own rules. Criteria for coverage, prior authorization, and co-pays can vary widely, even within the same country. If you’re unsure, it’s best to contact your insurance company directly and ask for the exact requirements for migraine treatments.

2.2 Cost

• Surveys in Migraine Buddy show 54.6% of patients worry about cost when considering anti-CGRPs【MB Anti-CGRP Survey】.

• Many discontinue anti-CGRPs due to out-of-pocket burden.

2.3 Expertise

• 40.5% of Migraine Buddy users said their doctor lacked migraine expertise【Healthcare System Survey】.

• Many first see a GP (83%), while headache specialists remain rare.

3. Why Tracking Matters

Tracking is the patient’s most powerful tool:

• For insurance: documentation of failed treatments supports approval of newer therapies.

• For doctors: helps guide treatment changes.

• For patients: reveals triggers, patterns, side effects (e.g., nausea from triptans).

Migraine Buddy users  who tracked consistently reported feeling more confident explaining their condition to doctors in person and even more in teleconsultations【Telemedicine Survey】.

4. How Telemedicine Can Help

Telemedicine is increasingly closing the access gap:

• Easier scheduling, shorter waits, and care from home【Telemedicine Journey Survey】.

• Patients report feeling more comfortable explaining migraine online than in rushed clinics.

• Doctors on platforms like PfizerForAll or Upscript are often more open to co-creating treatment plans, and patients can choose doctors based on expertise, values, and experience.

Telemedicine also speeds up time to prescription and diagnosis【AMF】【MB Telemedicine Survey】.

6. Key Takeaways

• Migraine treatment is a journey of trial and error.

• Both migraine-specific and non-specific drugs play important roles.

• Tracking treatment efficacy and side effects with tools like Migraine Buddy helps patients move faster through the system.

• Insurance and cost remain barriers, but telemedicine offers new hope for access and patient-centered care.

 

7. FAQ

Q1: What’s the difference between acute and preventive migraine treatments?
Acute treatments stop attacks after they have started (e.g., triptans, NSAIDs). Preventives reduce frequency/severity when taken regularly even on days when you don’t have an attack (daily, monthly, quarterly) (e.g., propranolol, anti-CGRPs, Botox).

Q2: Why do doctors prescribe non-migraine drugs for migraine?
They are evidence-based, affordable, and effective for many. Propranolol and topiramate, for example, reduce migraine days significantly. They also can have important side effects, so the benefit-risk balance needs to be discussed with your doctor【The Migraine Trust】.

Q3: Why do I have to try older medications first?
Insurance usually requires “step therapy”: these meds genuinely help many patients so why spend more if cheap drugs work? Again it’s important to track and present detailed reports in case they do not work for you.

Q4: Are CGRP monoclonal antibodies effective?
Yes, trials show they cut migraine days by half in many patients【The Migraine Trust】. Migraine Buddy survey data shows many patients who accessed them reported fewer migraine days, though cost remains a barrier.

Q5: Why does insurance deny migraine medications?
Cost: anti-CGRPs and gepants are expensive, so insurers require proof cheaper meds failed.

Q6: What role does tracking play in migraine treatment?
Tracking provides the evidence doctors and insurers need. It also helps patients identify patterns, triggers, and side effects.

Q7: How can telemedicine help me access migraine care?
It shortens wait times, gives access to specialists, and allows patients to choose doctors aligned with their values.

References & Resources

• World Health Organization (WHO): Neurological disorders – migraine prevalence and impact
  👉 https://www.who.int/news-room/fact-sheets/detail/headache-disorders

• The Migraine Trust: Preventive treatments (beta-blockers, anticonvulsants, antidepressants, CGRPs)
  👉 https://migrainetrust.org/live-with-migraine/healthcare/treatments/preventive-treatment/

• American Migraine Foundation (AMF):

  • Preventive migraine treatment overview
    👉 https://americanmigrainefoundation.org/resource-library/acute-and-preventive-treatment/

  • Medication Overuse Headache (MOH)
    👉 https://americanmigrainefoundation.org/resource-library/medication-overuse-headache/

• National Institute for Health and Care Excellence (NICE, UK): CGRP guidance
  👉 https://www.nice.org.uk/guidance/ta682

• Australian PBS (Pharmaceutical Benefits Scheme): Migraine treatment subsidies (Aimovig, Ajovy, Emgality, Vyepti, Botox)
  👉 https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/pbs-listing-expanded-to-include-treatment-resistant-high-frequency-episodic-migraine

• Migraine Buddy Community Surveys & Data:

  • Healthcare System Support Survey (doctor expertise & access)

  • Anti-CGRP Survey (cost & coverage barriers)

  • Telemedicine Survey (comfort with online consultations)

  • Opioids Survey (risks in ER/GP settings)

• Migraine Buddy App Data:
  Real-world treatment usage patterns based on in-app medication tracking (acute vs. preventive, chronicity differences).